Cybin (NASDAQ:HELP) CFO Buys $38,730.00 in Stock

Cybin Inc. (NASDAQ:HELP) CFO Greg Cavers purchased 3,000 shares of Cybin stock in a transaction on Tuesday, September 29th. The stock was bought at an average cost of $12.91 per share, for a total transaction of $38,730.00. Following the transaction, the chief financial officer directly owned 3,000 shares in the company, valued at $38,730. This represents a ? increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Cybin Stock Performance

Shares of HELP traded down $0.38 during midday trading on Thursday, hitting $11.91. The company had a trading volume of 1,326,987 shares, compared to its average volume of 1,653,574. Cybin Inc. has a 1 year low of $3.76 and a 1 year high of $15.15. The company’s 50-day simple moving average is $11.67 and its 200-day simple moving average is $7.53.

Cybin (NASDAQ:HELP) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.91) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.11). On average, analysts predict that Cybin Inc. will post -2.95 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Cybin

An institutional investor recently bought a new position in Cybin stock. AXQ Capital LP purchased a new position in shares of Cybin Inc. (NASDAQ:HELP) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 11,315 shares of the company’s stock, valued at approximately $75,000. 17.94% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on HELP. TD Cowen increased their price objective on Cybin from $8.00 to $62.00 and gave the company a “buy” rating in a report on Thursday, August 20th. Barclays initiated coverage on Cybin in a research note on Friday, September 18th. They set an “overweight” rating and a $35.00 target price for the company. Wells Fargo & Company initiated coverage on shares of Cybin in a research note on Monday, July 27th. They issued an “overweight” rating and a $16.00 price target on the stock. Finally, Wall Street Zen raised shares of Cybin from a “strong sell” rating to a “sell” rating in a report on Saturday, August 29th. Six equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $46.33.

About Cybin

Cybin Inc is a clinical-stage biopharmaceutical company focused on developing psychedelic-based therapeutics for the treatment of mental health conditions. The company combines drug discovery, clinical development and proprietary formulation technologies to design potentially more efficient and scalable psychedelic treatments.

Cybin’s development programs have included CYB003, an investigational deuterated psilocybin analog being studied for major depressive disorder, and CYB004, an investigational deuterated DMT molecule being evaluated for generalized anxiety disorder and other mental health indications.